Alterations in TSC2 have been identified in 3.39% of all cancers, with a higher prevalence in lung adenocarcinoma, colon adenocarcinoma, breast invasive ductal carcinoma, endometrial endometrioid adenocarcinoma, and high-grade ovarian serous adenocarcinoma [65]. This evidence concerns the gene TSC2 and colon adenocarcinoma.